Myxedema Coma Market Size & Share, Growth Statistics 2035

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Myxedema Coma Market size is poised to reach USD 5 Billion by the end of 2035, growing at a CAGR of 4% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of myxedema coma was USD 2 Billion. The reason behind the growth is impelled by a higher prevalence of diabetes 1. Type 1 diabetes could be linked to other diseases including Hashimoto’s thyroiditis, which is considered a major cause of hypothyroidism. Moreover, it causes damage to the thyroid gland and may reduce the level of thyroid hormones in the body. Globally, there were approximately 7 million people with type 1 diabetes in 2021.

The growing geriatric population is believed to fuel the myxedema coma market growth. The elderly population is more prone to thyroid dysfunction and other age-related diseases such as diabetes which may increase the risk of myxedema coma. Lately, over 8% of the world's population, is over the age of 65, and by 2050, this ratio is anticipated to rise to around 15%.

Get more information on this report: Request Free Sample PDF

Myxedema Coma Market: Key Insights

Base Year	2022
Forecast Year	2023-2035
CAGR	~4%
Base Year Market Size (2022)	~ USD 2 Billion
Forecast Year Market Size (2035)	~ USD 5 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Myxedema Coma Market: Growth Drivers and Challenges

Growth Drivers

Growing Incidence of Pneumonia- Untreated hypothyroidism can affect the immune system making patients more prone to pneumonia which might increase the risk of the development of myxedema coma.
Globally, More than 650,000 children under the age of five lose their lives to pneumonia every year, including more than 150,000 newborns.
Spiking Prevalence of Chronic Stress- Pre-existing medical conditions may become worse under prolonged stress, and fluctuations in hormones can be brought on by both short-term and long-term stress which can affect the hypothalamic-pituitary-adrenal axis impacting the thyroid hormone production, leading to an increase risk of developing myxedema coma.
According to statistics, in the UK more than 150,000 people die each year from a stress-related ailment.
Increasing Cases of Urine Infections- One of the most typical bacterial infections is UTIs, which may be brought on by bacterial or fungal infections. If UTI is left untreated it may become worse and lead to the development of conditions such as myxedema coma.
Every year, over 140 million people worldwide are affected by urinary tract infections (UTIs).
Rising Surgical Procedures- Surgical procedures are an excellent choice for treating most ailments owing to the benefits and outcomes provided. Anesthesia is frequently administered during surgical procedures, which can cause severe, potentially fatal myxedema by impairing the thyroid gland's ability to function normally.
According to the World Health Organization (WHO), millions of individuals undergo surgery every year, and it is estimated that surgical procedures account for 13% of all disability-adjusted life years worldwide.

Challenges

High Cost of Treatment– Owing to the frequent need for hospitalization and extensive care, myxedema coma therapy could be costly. The expense of hospitalization could be significant since myxedema coma is often treated in a medical facility, which may include the price of hospital lodging, medical personnel, and medical equipment. Additionally, patients may require continuous care and monitoring after treatment for myxedema coma.
Limited Awareness Among People
Lack of Specific Treatment

Myxedema Coma Segmentation

Route of Administration (Oral, Injectable)

The oral segment in the myxedema coma market is estimated to gain a robust revenue share in the coming years owing to the growing preference of people for oral therapy. Compared to intravenous treatments, oral drugs carry a lesser risk of problems including infection or vein damage. A post-injection flare is thought to occur in about 2 in 50 persons a few hours after receiving an injection. The convenience of consuming oral drugs and the cost-effectiveness also propels the segment’s growth.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)

Myxedema coma market from the hospital pharmacies segment is set to garner a notable share shortly. Thyroid hormone replacement therapy, which is the drug used to treat myxedema coma, is commonly accessible in hospital pharmacies where patients receive for this potentially fatal illness. Moreover, levothyroxine (T4) and liothyronine (T3) hormones, along with other medications used to treat myxedema coma, are often taken with the assistance of a medical practitioner. The effectiveness of the patient’s treatment must be closely monitored, and the dosage of the medicine should be changed as necessary.

Our in-depth analysis of the global myxedema coma market includes the following segments:

Route of Administration	Oral Injectable
Indication	Hypothyroidism Hypocortisolemia Hypoventilation Hypoglycemia Hypotension
Distribution Channel	Hospital Pharmacies Retail Pharmacies Drug Stores Online Pharmacies
Drug Class	Synthetic Natural

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Myxedema Coma Industry- Regional Synopsis

North American Market Forecast

Myxedema coma market in North America is predicted to account for the largest share of 38% by the end of 2035 impelled by the growing prevalence of obesity. In the USA, obesity is a significant public health issue, which affects over 30% of Americans. Moreover, patients with obesity have a higher chance of developing hypothyroidism which may lead to myxedema coma if left untreated. According to the estimates, during the COVID-19 pandemic, the obesity rate in the U.S. increased by over 2% in 2021.

APAC Market Statistics

The Asia Pacific myxedema coma market is estimated to be the second largest, during the forecast timeframe led by a higher prevalence of iodine deficiency. One of the most frequent causes of hypothyroidism in the globe is iodine deficiency, which is highly prevalent in several nations in the Asia Pacific region such as South and Southeast Asia. As a result, iodine supplementation and thyroid hormone replacement therapy are becoming popular in the region.

For instance, no state in India is immune to iodine deficiency, and more than 150 million people are in danger' of developing iodine deficiency.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Myxedema Coma Market

AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Merck & Co., Inc.
Pfizer Inc.
GSK plc.
Sanofi Global
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Novartis AG
Lannett Company, Inc.
Zydus Lifesciences

In The News

Mylan N.V received FDA approval for Ermeza (levothyroxine), which is available in oral dose formulations such as generic tablet and capsule forms, and can be used as a supplemental treatment to surgery and radioiodine therapy or as a replacement therapy for congenital or acquired hypothyroidism in adult and pediatric patients.
Zydus Lifesciences got approval from the US Food and Drug Administration (USFDA) for marketing the Levothyroxine Sodium Injection which is used to treat myxedema coma or extreme hypothyroidism.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the myxedema coma market?

Ans: Higher prevalence of type 1 diabetes and the growing geriatric population are the major factors driving the growth of the market.

2) What would be the CAGR of the myxedema coma market over the forecast period?

Ans: The market size of myxedema coma is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023 â€“ 2035.

3) Who are the major players dominating the myxedema coma market?

Ans: The major players in the market are Merck & Co., Inc., Pfizer Inc., GSK plc., Sanofi Global, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Lannett Company, Inc., Zydus Lifesciences.

4) Which segment captures the largest market size in the route of administration segment in the myxedema coma market?

Ans: The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

5) Who are the major players dominating the myxedema coma market?

Ans: : The major players in the market are AbbVie Inc., Merck & Co., Inc., Pfizer Inc., GSK plc., and more.

6) Which region will provide more business opportunities for the growth of the myxedema coma market in the future?

Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.